Rocket Pharmaceuticals (RCKT) PT Raised to $24 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts RCKT Hot Sheet
Price: $2.56 -2.66%
Rating Summary:
16 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
16 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Raymond James analyst Timur Ivannikov raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $24.00 (from $22.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral
- RPM International (RPM) PT Lowered to $117 at KeyBanc
- Pepsico (PEP) PT Lowered to $140 at Piper Sandler as 'Cost Pressures Steal Spotlight'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
